Adipose stem cell therapy (Anterogen)

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameAdipose stem cell therapy (Anterogen)
Drug Alias NameAdipocellAdipoPlusAutologous adipose tissue-derived adipose cellCupistemQueencell +[12] 
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Adipose-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsBurnsEpidermolysis Bullosa DystrophicaDiabetic Foot +[6] 
Global Approved IndicationsCrohn Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2012/01/01
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAnterogen Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAnterogen Co Ltd
Inactive CompaniesYonsei University
Active IndicationsBurnsEpidermolysis Bullosa DystrophicaDiabetic Foot +[4] 
Inactive IndicationsFecal IncontinenceTennis Elbow

Other Information

ATC CodeN/A
Related LinksN/A